[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369712-105":59,"doc-detail-369712-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cannabinoid-derived-product-is-a-potential-novel-therapeutic-for-papillary-thyroid-carcinoma","Cannabinoid Derived Product is a Potential Novel Therapeutic for Papillary Thyroid Carcinoma","","Papillary thyroid carcinoma (PTC) is the most common thyroid cancer, typically presenting as an asymptomatic neck mass and having an excellent prognosis after surgery. Ongoing research seeks non-invasive therapeutic options with minimal adverse effects. This study evaluates a cannabinoid-based product (BRF1-A) and its anti-cancer potential by modulating gene expression in K1 papillary thyroid cancer cells, focusing on TP53, c-Myc, and BCL-2.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cannabinoid-derived-product-is-a-potential-novel-therapeutic-for-papillary-thyroid-carcinoma/369712/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cannabinoid-derived-product-is-a-potential-novel-therapeutic-for-papillary-thyroid-carcinoma/369712.png","ImageObject",300,407,{"name":92,"@type":93},"Pentious","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of the study on BRF1-A?","Question",{"text":112,"@type":113},"The study investigates the cannabinoid-based product BRF1-A and its potential anti-cancer effects in K1 papillary thyroid cancer cells through modulation of gene expression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was BRF1-A tested on K1 thyroid cancer cells?",{"text":117,"@type":113},"BRF1A was co-cultured with K1 cells and incubated at 37°C under 5% CO2 for 24 and 48 hours. Cell viability was measured using a trypan blue exclusion assay, and gene expression changes were assessed by qRT-PCR.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings regarding gene expression and viability?",{"text":121,"@type":113},"BRF1A decreased viability of K1 PTC cells in a dose- and time-dependent manner. After 24 hours, it increased TP53 expression and decreased BCL-2 and c-Myc expression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369712,1790219383,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Cannabinoid Derived Product is a Potential Novel Therapeutic for Papillary Thyroid Carcinoma  \nIntegrative Cancer Therapies Volume 24: 1–7 © The Author(s) 2025 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/15347354251332966](DOI: 10.1177/15347354251332966)[ ](DOI: 10.1177/15347354251332966)[journals.sagepub.com/home/ict](journals.sagepub.com/home/ict)  \nCarolina Taico Oliva, BS 1\\#, Ibrahim Musa, PhD 1\\#, Fariba Ardalani, MS 1, Joseph Breslin, PhD2, Nan Yang, PhD3, Augustine Moscatello, MD 1,3, Janine Rotsides, MD 1,3, Raj Tiwari, PhD 1,4, Jan Geliebter, PhD 1,4,  \nand Xiu-Min Li, MD, MS, MPH 1,4  \nAbstract  \nRationale: Papillary thyroid carcinoma (PTC) is the most common thyroid cancer that typically affects women ages 20 to 50, presenting as an asymptomatic neck mass. Treatment with total or partial thyroidectomy shows an excellent prognosis. However, investigation of non-invasive therapeutic options with minimal adverse effects is ongoing. This study seeks to investigate the K1 cell line, which consists of PTC cells obtained from metastatic tumors of well-differentiated PTC. Objective: Our investigation focuses on a cannabinoid-based product (named BRF1-A) and its potential anti-cancer effects through modulation of gene expression. We investigated its effects on gene expression of p53, c-Myc, and BCL-2 in K1 papillary thyroid cancer cells.  \nMethods: BRF1A was co-cultured with K1 cell line (1 × 106 cells/ml) and incubated at 37°C under 5% CO2 for 24 and 48 hours. After the culture time points, the cells were harvested, and cell viability was determined via trypan blue exclusion assay. Using qRT-PCR, we determined the effect on the gene expression of TP53, c-Myc, and BCL-2.  \nResults: Results show that the BRF1A decreased the viability of K1 PTC cells in a dose and time-dependent manner. Within 24 hours, the cannabinoid- containing product increased the gene expression of TP53 and decreased the gene expression of BCL-2 and c-Myc in K1 PTC cells.  \nConclusion: The results suggest that the cannabinoid-containing product BRF1A interacts as a potential regulator in well-differentiated thyroid cancer with the upregulation of p53 and downregulation of BLC-2 and c-Myc. Further in vitro and in vivo studies are needed to understand the exact mechanism and therapeutic potential of the cannabinoid-containing products in papillary thyroid cancer.  \nKeywords  \ncannabinol, senescence, tetrahydrocannabinol, cannabidiol, cancer suppressor genes  \nReceived: September 7, 2024; accepted: March 21, 2025  \nIntroduction  \nPapillary thyroid carcinoma (PTC) is the most frequent typeof malignant epithelial growth of thyroid tissue, with an excellent prognosis following surgical intervention.1 Novel investigations with the use of human thyroid cancer cell lines focus on the genetic alterations that determine tumorigenesis and disease progression to improve the management of PTC. Driver mutations in PTC such as BRAF,2 RAS,3 and RETPTC2 have been identified, as well as a less common p53 mutation. Mutations in p53 are well-known features in  \n1 New York Medical College, Valhalla, USA 2Breslin Research Foundation, Taos, NM, USA  \n3General Nutraceutical Technology LLC, Elmsford, NY, USA 4Westchester Medical Center, Valhalla NY, USA  \n\\#Equal first author.  \nCorresponding Author:  \nXiu-Min Li, MD, MS, Microbiology & Immunology, Professor of Otolaryngology (ENT), School of Medicine, New York Medical College, Westchester Medical Center, Basic Sciences Building Room 348, 40 Sunshine Cottage Road, Valhalla, NY 10595, USA. [Email: XiuMin_Li@NYMC.edu](Email: XiuMin_Li@NYMC.edu)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons AttributionNonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reprod","cbCain3l8TUoRkQS","https://ap.wps.com/l/cbCain3l8TUoRkQS","pdf",490163,"English","# Abstract\n## Rationale\n## Objective\n## Methods\n## Results\n## Conclusion\n# Keywords\n# Introduction","[{\"question\":\"What is the purpose of the study on BRF1-A?\",\"answer\":\"The study investigates the cannabinoid-based product BRF1-A and its potential anti-cancer effects in K1 papillary thyroid cancer cells through modulation of gene expression.\"},{\"question\":\"How was BRF1-A tested on K1 thyroid cancer cells?\",\"answer\":\"BRF1A was co-cultured with K1 cells and incubated at 37°C under 5% CO2 for 24 and 48 hours. Cell viability was measured using a trypan blue exclusion assay, and gene expression changes were assessed by qRT-PCR.\"},{\"question\":\"What were the main findings regarding gene expression and viability?\",\"answer\":\"BRF1A decreased viability of K1 PTC cells in a dose- and time-dependent manner. After 24 hours, it increased TP53 expression and decreased BCL-2 and c-Myc expression.\"}]","Cannabinoid Derived Product is a Potential Novel Therapeutic for Papillary Thyroid Carcinoma | PDF",1790184187,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d2c1a25de86e23cb05b54aa3977f5a61.webp",983,1276,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c6827537e203962f82c1895bb1c2c2b2.webp",982,1275,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ceed2b74f91bdabc678697657c6343f9.webp",981,1273,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f276ede6c36eef41cbd9735b292ecb5.webp",980,1272]